While Danchura and her husband slept, the cat jumped onto the bed and slowly walked across her body. As the cat stepped on one of her breasts, Danchura was struck by an strong shot of pain.

A lump was discovered.

“I sort of went, ‘Oh geez, there’s definitely something wrong there,’” she said.

The cat was considered a hero by finding a cancerous tumour in Judy Danchura’s breast She made a doctor’s appointment,then there were the tests and ultimately the diagnosis of cancer.

Due to the early detection of the malignant tumour, and since she was able to start treatment right away, Danchura’s possibility of survival is estimated at 95 per cent.

She is grateful to the cat, which she has now adopted.

“I don’t know what my chances of survival would have been without him,” she said. “I know I’d certainly be far worse off.”

Danchura named the cat Sumo but likes to refer to him as her “furry four-footed angel.”

“I sometimes feel overwhelmed because I feel humbled,” she said. “I can’t understand why this animal turned up for me.”

Tamoxifen is given to most women diagnosed with breast cancer to prevent the cancer returning.

But not all women respond to the drug – experts estimate a third get no benefit.

The work in the journal Cancer Research suggests the problem is too much of a gene called FGFR1.

This discovery could lead to new treatments for these women as scientists “switch off” the action of FGFR1, enabling Tamoxifen to work.

The team of scientists in the Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research have already shown this is possible in the lab.

They introduced a drug which “switched off” the action of FGFR1.

Once FGFR1 was stopped, hormone-based treatments like Tamoxifen could get back to work in destroying cancer cells, they found.

The researchers believe this could ultimately help thousands of women each year.

They say one in 10 breast cancer patients has too much of the FGFR1 gene.

Dr Nick Turner, who led the research, said: “Understanding how this gene can cause Tamoxifen resistance reveals a new drug target for treating breast cancers in patients who would otherwise have a poor outcome.

“There are a number of drugs in development that stop FGFR1 working, and clinical studies are investigating whether these drugs work against cancers with too many copies of this gene.

“The next step is to set up a clinical trial to see whether a drug that blocks the action of this gene can counteract hormone therapy resistance in breast cancer patients.

“If these trials confirm our lab work we could be on the verge of a potentially exciting new treatment for breast cancer.”

Dr Lesley Walker of Cancer Research UK, the charity which helped fund the work, said: “Cracking the problem of resistance to treatments such as Tamoxifen would be a major advance in treating breast cancer.”

Breast cancer is the most common cancer in the UK affecting more than 45,500 women each year.

Tamoxifen blocks the female sex hormone oestrogen that fuels the growth of some breast tumours.

Here are the 10 ways.

1. Moderate your alcohol consumption: drinking alcohol increases the risks of cancers of the pharynx, mouth, larynx, rectum, esophagus, colon, and liver. Women should limit themselves to one alcoholic beverage per day. Men should limit themselves to two.

2. Eat plenty of raw fruits and vegetables: The American Cancer Society recommendation is to eat five servings of fruits and vegetables daily since they are loaded with vitamins, minerals, antioxidants and other substances that decrease the risk of cancer. Recent studies have shown that the connection between eating vegetables and fruits and lower risk of cancer risk isn’t as strong as once thought. However the majority of researchers still subscribe to the idea that a plant-based diet is one of the best ways to secure overall health.

3. Think about chemoprevention: Chemoprevention is using natural or synthetic compounds to reduce the cancer risk or recurrence. Tamoxifen, prescribed to prevent breast cancer in women, is the most famous chemoprevention agent. The downside: chemoprevention drugs may have serious side effects.

4. Decrease the amount of fat in your diet: Studies suggest that high-fat diets are linked to several types of cancer, including postmenopausal breast, colon, and lung cancer. High-fat diets are usually high in calories and increase the risk of obesity. More study is required to understand which types of fat should be avoided and what amount effects cancer risk.

5. Stay within your ideal weight zone: Being overweight will tend to increase the risk of postmenopausal breast cancer as well as cancers of the endometrium, colon, esophagus and kidney. There have been studies showing that obesity increases the risk of cancers of the prostate, liver, stomach, gallbladder, pancreas, ovary and cervix. Some studies estimate that excess weight is a factor in 15 to 20 percent of cancer-related deaths.

6. Get screening exams: Pap tests, mammograms, colonoscopies and other routine screenings obviously don’t prevent cancer. But screenings will detect cancers early, when treatment is more likely to be successful.

7. Exercise: Evidence increasingly suggests that people who exercise have lower risk of certain cancers than those who are sedentary. From 45 to 60 minutes of moderate to vigorous activity a day, on most days of the week, is considered optimal to decrease the risk of breast and colorectal cancers.

8. Limit radiation exposure: Ultraviolet (UV) radiation, from the sun, sunlamps or commercial tanning beds, is the primary cause of skin cancer.

9. Stop smoking or don’t start smoking: The risk of cancers caused by smoking is proportional with the length of time a person has smoked and the quantity of cigarettes smoked. Lung cancer, the leading cause of cancer death among Americans is caused by smoking. Quitting smoking decreases the risk of lung cancer and it is never too late to take action on this.

10. Guard yourself from infection: Infections caused by viruses are well known to be risk factors for a wide variety of cancers. Human papillomavirus (HPV), which is a sexually transmitted disease, is the most frequent cause of cervical cancer. Chronic hepatitis B and hepatitis C aggravate the risk of liver cancer. They are usually spread by contact with contaminated blood, contaminated needles or sex. Human immunodeficiency virus (HIV), the virus that leads to AIDS, additionally increase the risk of many cancers.

Eating a pomegranate everyday can help prevent breast cancer, new research reveals. American scientists are saying pomegranates contain chemical agents known as phytochemicals, which play an important role in the prevention of breast cancer.

Scientists at the City of Hope Cancer Research and Treatment Center in Duarte, California, have discovered that the fruit contains a large amount of the phytochemical called ellagitannins. The phytochemical has an inhibitory effect on the enzyme aromatase, which plays a pivotal role in making the hormone oestrogen, which in turn leads to most of the cases of breast cancer. Meanwhile, many patients who suffer from the breast cancer take medicines which are actually aromatase inhibitors.

The research which was published in the journal ‘Cancer Prevention Research’ highlights the fact that laboratory experiments that were carried out took into account around 10 compounds from the pomegranate and their effects were subsequently tested. Among the compounds which were taken into consideration, urolithin B was seen to be the most effective in preventing breast cancer.

However, researcher Shiuan Chen, who was intrinsically involved with the research, emphasized that the compounds did not turn out to be as effective as actual drugs due to which researchers have warned the patients against using the fruit as a replacement of the aromatase inhibitor medicines. At the same time, it has been implied that the results are not conclusive and further tests need to be carried out in order to confirm the findings. However, the findings are being considered to be significant as it might herald a new era in breast cancer treatment.

Read more: Pomegranates and Cancer.

“I was diagnosed and treated for stage one cancer (two different types) in both breasts. The cancer was detected at an early stage thanks to a mammogram and the work of a remarkable physician who insisted on investigating beyond what the mammogram could show,” she writes, “I have had two operations and my prognosis for a full recovery is good.”

Heinz editorializes that women should ignore new guidelines from the U.S. Preventive Services Task Force that stated women at average risk don’t need regular screenings and that mammograms in older women can be reduced to every two years, versus previous annual guidelines.

She opines that the task force is “predisposed to choose numbers over people.”

“Our busy lives are full of those. What we need are more reasons to keep those appointments, more support of the value of prevention and refinement of diagnostic procedures, and more choices.”

The Obama administration has distanced itself from the task force’s recommendations amid backlash from women’s and medical groups. The Department of Health and Human Services did not endorse the findings.

The Associated Press reported that Heinz was treated by a surgeon at Massachusetts General Hospital that she had recommended to Elizabeth Edwards, the wife of Kerry’s 2004 running mate John Edwards, who was diagnosed with breast cancer shortly after their failed presidential bid.

Heinz told AP she has not spoken with Elizabeth Edwards since her own diagnosis.

Several large clinical trials have shown that tamoxifen can decrease the risk of breast cancer in high-risk women. There are, however, two issues that have prevented widespread use of tamoxifen for breast cancer prevention:

* Who is at risk? The definition of who is high risk is problematic and differs from trial to trial. Generally, high risk includes women with a family history of breast cancer, early menarche, later or no childbirth, or previous breast biopsy, even if negative.

* What are the side effects? In one study, it was found that less than one in five women at high risk would take tamoxifen due to their fears of side effects and the fact that they assumed they were at relatively low risk for developing breast cancer.

Two reports in the February 21, 2007 issue of the Journal of the National Cancer Institute document that tamoxifen can prevent hormone-positive breast cancer in women at high risk.

Researchers affiliated with the Royal Marsden Randomized, Double-Blinded Tamoxifen Breast Cancer Prevention Trial reported 20-year follow-up data. This trial randomly allocated 2,494 women at high risk of developing breast cancer to receive tamoxifen or placebo for eight years. A total of 82 women in the tamoxifen group and 104 in the placebo group developed invasive breast cancer. Researchers affiliated with the first International Breast Cancer Intervention Study (IBIS-I) reported that the breast cancer preventative effects of tamoxifen persist for at least 10 years after a five-year treatment period. This trial randomly allocated 7,145 women at increased risk for developing breast cancer to receive five years of tamoxifen or placebo. With a 96-month follow-up, there were 142 breast cancers in the tamoxifen group and 195 in the placebo group. They observed a preventive effect during the entire period of observation. The main side effects were an increased risk of deep-vein thrombosis and pulmonary embolism during but not after tamoxifen treatment. The estimated risk for developing estrogen receptor-positive breast cancer was 34% lower in the tamoxifen group.

The authors of the present trial sought to determine why few women with increased risk of breast cancer use tamoxifen for chemoprevention. They evaluated 632 women with an average 2.56% risk of developing breast cancer within five years. These women were presented with a tailored decision aid concerning the effectiveness of chemoprevention with tamoxifen and the known side effects. After reviewing the decision aid, 29% of women said they would seek more information from their own physician, and 6% said they would agree to take tamoxifen. These researchers thought that these women had adequate knowledge to make a decision. The stated: “Participants were concerned about the risks of tamoxifen, and many believed that the benefits of tamoxifen did not outweigh the risks.”

Discovering Key to Tamoxifen’s Effectiveness in Treating Breast Cancer may Mean New Treatments

Ana Ripoll, Rector of Universitat Aut-noma de Barcelona (UAB), and Pedro Barato, President of “Organizaci-n Interprofesional del Aceite de Oliva Espa-ol”, signed a research agreement to carry out an in depth study on how the intake of olive oil can work towards preventing and fighting against breast cancer. The Multidisciplinary Group on Breast Cancer Research (GMECM), directed by Dr Eduard Escrich, lecturer of the Department of Cell Biology, Physiology and Immunology, will be working on this research project during the next five years. GMECM has demonstrated in previous researches that a moderate intake of virgin olive oil slows down the spreading of this cancer.

Researchers at GMECM aim to determine the possible activity of common components of the human diet with the objective of formulating scientific opinions on the health of the population or levels of risk, all within the field of breast cancer prevention. Among the results obtained until now researchers highlight the fact that a moderate intake of virgin olive oil can slow down the spreading of this cancer due to the action of mechanisms which counterattack the possible harmful effects of fats, while an excessive intake of seed oils has damaging effects.

In the study, which will begin this coming year, researchers will continue to study the effects olive oil can have on this type of cancer, with experimental studies and with human cell lines and samples. Among the research studies to be carried out, some of the most prominent focus on the effects fats and oils can have on mammary tumours, and especially those of extra virgin olive oil, and an analysis of the molecular changes found in these tumours in all of the genome and in the specific genes implicated in this pathology.

Olive oil lowers risk of breast cancer

The findings, published in the October 2009 issue of Cancer Epidemiology, Biomarkers, and Prevention, highlight the need to develop specific health policies and interventions to address social disparities.

Although prior studies have focused on factors that contribute to disparities in specific cancers, the Mailman School researchers’ goal in this study was to understand why racial/ethnic disparities emerge in some cancers but not others. The study used data from more than 580,000 cancer cases in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) registries to compare racial/ethnic differences in survival across a spectrum of cancers, classified according to their five-year relative survival rates as a measure of how amenable each cancer is to medical interventions. The authors hypothesized that racial/ethnic disparities increase as medical interventions improve overall survival because individuals with more socioeconomic resources are in a better position to exploit medical advances to protect their health.

The results found that, as compared with whites, substantial survival disparities existed in more treatable cancers in African-Americans, American Indians/Alaska Natives, Hispanics, and several subgroups of the Asian/Pacific Islander population.

The University of Albany has connected the pregnancy protein alpha-fetoprotein (AFP) to breast cancer slowing down in rats exposed to pregnancy hormones such as estrogen, progesterone, or human chorionic gonadotropin.

These pregnancy hormones were shown by the authors to induce AFP during the term of pregnancy.

The hormones also appear to inhibit breast cancer growth in previous rat studies, although estrogen and progesterone fuel the growth of breast cancer in humans.

Herbert Jacobson, PhD, who has been studying AFP in rats for over twenty years, believes the protein is the cause of the pregnancy-related reduction in breast cancer risk.

“Twenty-five years ago I deduced that this must be the agent responsible for lowering breast cancer risk in women who have been pregnant,” he tells WebMD. “And the research we have done since then supports this hypothesis.”

Pregnancy, particularly before the 30 years old, lowers a woman’s lifetime risk of developing breast cancer. Also having more than one child is preventative.

Alpha-fetoprotein is produced by the fetus, and size of the protein during pregnancy can help to screen out possible birth defects.

Extremely high AFP levels portend the appearance of neural tube defects or an abdominal wall defect known as omphalocele, and extremely low levels suggest Down syndrome.

The protein is usually not detected in the blood of healthy men and women who are not yet pregnant. In these groups, elevated AFP levels suggest the presence of some cancers.

In their new study, in the December issue of Cancer Prevention Research, Jacobson and associates treated cancer-exposed rats that were not pregnant with estrogen, estrogen plus progesterone, or human chorionic gonadotropin (HCG).

As in previous studies, all of these treatments are associated with reduced levels of breast cancers in the high-risk rats.

Each of the hormone treatments were also connected with elevated AFP levels and AFP was found to slow down the growth of breast cancer cells in lab cultures.

“Hormones in pregnancy, such as estrogen, all induce AFP, which directly inhibits the growth of breast cancer,” Jacobson says in a news release.
Second Opinion

However, devil’s advocate and cancer specialist Powel Brown, MD, PhD, says the research does not show that this is true beyond a shadow of a doubt.

As is the case with these kinds of studies, says Sandy Hutchens Cancer Prevention, there will be those that promote the idea and there will be detractors. We await the results of further studies and even possibly some proof on this unique view into breast cancer prevention.

Pregnant and Facing Breast Cancer

Breast cancer often can be treated with early detection. That’s why health insurance that pays for mammograms is especially important. But mammography rates declined between 2003 and 2005, with a notable decrease for Hispanic women (from 65 percent to 59 percent) and African-American women (from 70 percent to 65 percent). Never mind the controversy over mammograms for women under 50; an estimated one in five women over 50 has not received a mammogram in the past two years.

Everyone needs health insurance to keep healthy, yet women are disproportionately underinsured. An estimated 21 million women and girls went without health insurance in 2007, according to the U.S. Census Bureau. And a recent congressional report found that 18 percent of all women not eligible for Medicare are uninsured.

Why are so many women left uncovered? Perhaps it’s because many medical situations faced by women are treated as pre-existing conditions, including breast cancer. The National Cancer Institute estimated that in 2004 approximately 2.4 million women had a history of breast cancer. Without continuing coverage, cancer survivors face steep risks.

Health Insurance Facts: Fighting Cancer With No Insurance

Why are women falling behind in insurance coverage faster than men? According to the Department of Health and Human Services, various factors restrict women’s access to health care, which include a vast array of “pre-existing conditions” such as breast cancer, pregnancy, caesarian section and domestic violence. In addition, women are less likely to be employed full time, which makes them less likely to be eligible for employer-based health benefits. In fact, fewer than half of women have the option of obtaining employer-based coverage.

Any health care reform proposal should take that into consideration and include access to comprehensive care, including preventative care such as mammograms. Americans, men and women alike, understand this need. A recent poll commissioned by Moving Forward, a values-based research initiative developed by the Women Donors Network and the Communications Consortium, found that a strong majority of voters — 87 percent — think insurance companies should be required to cover women’s preventive care and screenings, such as contraception, Pap tests for cervical cancer and breast cancer screenings.

Public health experts recommend health insurance coverage be universal and available to all regardless of work status, place of residence, health status or other factors unrelated to need. Reform should be aimed at achieving quality outcomes and eliminating disparities as well as at being affordable. Coverage also needs to be continuous from birth until end of life without interruptions or delays, as gaps in existing coverage allow women to fall through the cracks.

Reform will bring health care to more American women and their families than ever before in our nation’s history. Women would do well to learn more about their stake in health care reform. One good resource is www.WomenandHealthCareReform.org. The best thing we can do to end breast cancer is to make sure all health insurance coverage is universal — not limited by exclusions due to pre-existing conditions — and includes preventative care and basic services such as breast and cervical cancer screenings. Let’s create a system that provides health care, not just sick care.

Wendy C. Wolf is a board member of Living Beyond Breast Cancer and Women Donors Network and leads WDN’s effort on reproductive and other health issues.